Patent · US Active

Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

US10899745B2 · kind B2 · utility

1Cited by

1References

2Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ke Chen · Sichuan, CN
Joerg Deerberg · Columbus, US
Dong Lin · Monmouth Junction, US
Michael Dummeldinger · Plainsboro, US
Bahar Inankur · New Brunswick, US
Sergei Kolotuchin · Princeton, US
Jun Li · Foster City, US
Amanda J. Rogers · Asbury, US
Victor W. Rosso · Plainsboro, US
Eric M. Simmons · Princeton, US
Daniel S. Treitler · Cranford, US
Jianji Wang
Michael J. Smith · Somerville, US
Tamas Benkovics · Somerville, US

Key dates

Filing date	Mar 29, 2018
Grant date	Jan 26, 2021
Priority date	—
Expiry date	Mar 29, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.